Phase I Study Of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

PURPOSE: Vorinostat, a histone deacetylase inhibitor, enhances cell death by the proteasome inhibitor bortezomib in vitro. We sought to test the combination clinically. EXPERIMENTAL DESIGN: A phase I trial evaluated sequential dose escalation of bortezomib at 1– 1.3 mg/ m(2) intravenously on days 1,...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Badros, Ashraf, Burger, Angelika M., Philip, Sunita, Niesvizky, Ruben, Kolla, Sarah S., Goloubeva, Olga, Harris, Carolynn, Zweibel, James, Wright, John J., Espinoza-Delgado, Igor, Baer, Maria R., Holleran, Julianne L., Egorin, Merrill J., Grant, Steven
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2009
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2758911/
https://ncbi.nlm.nih.gov/pubmed/19671864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2850
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk